SCHEMBL30294768

SCHEMBL30294768

CCOC(=O)c1ccc(C(F)(F)F)cc1Nc1ccc(F)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K2 P36507 1/20 0.48
MAP2K1 Q02750 1/20 0.48
MAPK14 Q16539 1/20 0.48
KDM4E B2RXH2 2/20 0.46
LMNA P02545 1/20 0.46
THRB P10828 2/20 0.45
POLB P06746 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
TSHR P16473 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MAPT P10636 3/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NTRK1 P04629 1/20 0.41
NTRK2 Q16620 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852778 1.00 MAP2K2 (0.48) MAP2K2MAP2K1MAPK14KDM4ELMNA
SCHEMBL22833395 0.91 KDM4E (0.46) MAP2K2MAP2K1KDM4ELMNATHRB
SCHEMBL29382578 0.91 KDM4E (0.46) MAP2K2MAP2K1KDM4ELMNATHRB
SCHEMBL30294404 0.89 MRGPRX4 (0.48) KDM4ELMNAPOLBSMN1; SMN2TDP1
SCHEMBL22852785 0.89 MRGPRX4 (0.48) KDM4ELMNAPOLBSMN1; SMN2TDP1
SCHEMBL26931183 0.89 KDM4E (0.44) MAP2K2MAP2K1KDM4ELMNATHRB
SCHEMBL22853000 0.88 KDM4E (0.43) MAP2K2MAP2K1KDM4ELMNATHRB
SCHEMBL30294309 0.88 CDC25B (0.47) KDM4ELMNATHRBPOLBSMN1; SMN2
SCHEMBL22853410 0.88 CDC25B (0.47) KDM4ELMNATHRBPOLBSMN1; SMN2
SCHEMBL30294403 0.88 KDM4E (0.43) MAP2K2MAP2K1KDM4ELMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B MAP2K2 2002/4885MAP2K1 2523/4885MAPK14 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.